The Fluoroquinolone Family
DNA Gyrase and Topoisomerase IV Inhibitors — Quinolone SAR
## Overview
Fluoroquinolones are broad-spectrum antibacterials that target bacterial type II topoisomerases: DNA gyrase (topoisomerase II) and topoisomerase IV. They form ternary "cleavage complexes" with the enzyme and DNA, trapping double-strand breaks in bacterial chromosomes. They are the most prescribed class of antibiotics for respiratory, urinary tract, and enteric infections. Nalidixic acid (1962) was the quinolone prototype; the addition of C6-fluorine (norfloxacin, 1978; ciprofloxacin, 1987) created the fluoroquinolone era.
## Target: DNA Gyrase and Topoisomerase IV
Bacterial DNA gyrase introduces negative supercoils to relieve torsional stress ahead of replication forks and transcription machinery. It works via a transient double-strand break, strand passage, and re-ligation cycle. Fluoroquinolones intercalate into the enzyme-DNA interface at the cleavage complex, blocking re-ligation and stabilizing the broken DNA. This causes rapid bactericidal killing through replication fork arrest and DNA double-strand breaks. Topoisomerase IV (primarily decatenation enzyme) is the primary target in gram-positive bacteria; gyrase is primary in gram-negatives.
## C3-C4 Pharmacophore: Metal Chelation Mechanism
X-ray crystallography of fluoroquinolone-gyrase-DNA complexes (PDB: 2XCT) confirmed that the C3 carboxylate and C4 keto oxygen chelate a divalent metal ion (Mg2+), which bridges the quinolone to key gyrase residues (GyrA Arg447, Ser447, Glu478) and DNA phosphates. This metal-mediated pharmacophore is uniquely bacterial—it is not replicated in human topoisomerase II binding, providing selectivity.
## C6-Fluorine: A Critical Innovation
The addition of fluorine at C6 (nalidixic acid → norfloxacin) increased antibacterial potency 10-100-fold. Mechanistically, C6-F increases penetration through gram-negative outer membrane porins (OmpF/OmpC) and enhances the drug-enzyme-DNA interaction. No clinically successful quinolone lacks this substitution.
## N1 and C7 SAR for Spectrum
The N1 group influences the "top" hydrophobic pocket in the gyrase-DNA interface. Cyclopropyl (ciprofloxacin, moxifloxacin, gemifloxacin) is superior to ethyl (norfloxacin, ofloxacin) by 4-8-fold in gyrase inhibition potency.
The C7 cyclic amine is the primary spectrum-modifying position. Piperazine (ciprofloxacin) confers activity against enteric gram-negatives and Pseudomonas (through OmpF permeation and efflux pump avoidance). Larger, more rigid C7 substituents (azabicyclo in moxifloxacin; 3-amino-1-pyrrolidinyl in levofloxacin) improve gram-positive (Streptococcus pneumoniae) and anaerobic coverage by enhancing topoisomerase IV affinity.
## C8 Methoxy and Anaerobic Activity
The C8 methoxy group (moxifloxacin, gatifloxacin) dramatically improves activity against anaerobes and gram-positive cocci. The mechanism involves enhanced stacking against the DNA base flanking the cleavage site and increased GyrB binding. However, C8-methoxy also increases QT-interval prolongation risk (HERG channel block), which contributed to the withdrawal of gatifloxacin for metabolic toxicity and restricts moxifloxacin use.
## Key Takeaways
- C3 carboxylate and C4 ketone chelate Mg2+ for gyrase-DNA cleavage complex stabilization—the essential pharmacophore
- C6-fluorine is a mandatory element for potency and membrane penetration
- Cyclopropyl at N1 is superior to ethyl by ~8-fold in gyrase binding
- C7 cyclic amines determine spectrum: piperazine for gram-negatives, bulkier amines for gram-positive/anaerobic coverage
- C8-methoxy adds anaerobic activity at the cost of increased cardiac toxicity risk
Ringkasan SAR
Key SAR findings for the fluoroquinolone family:
- C3 carboxylate and C4 keto group are the essential pharmacophore; they chelate Mg2+ ions that bridge the quinolone to gyrase subunit A (GyrA) Arg447 and DNA phosphates.
- C6 fluorine dramatically increases potency (10-100x) by enhancing DNA gyrase binding and improving cell penetration.
- C7 substituent governs gram-positive activity: piperazine (ciprofloxacin) provides activity vs gram-negatives and some gram-positives; pyrrolidine/spiro-carbon (levofloxacin, moxifloxacin) adds potent gram-positive and anaerobic activity.
- N1 substituent: ethyl (norfloxacin), cyclopropyl (ciprofloxacin/moxifloxacin) — cyclopropyl provides ~8x superior potency vs ethyl; fluorophenyl (older quinolones) less optimal.
- C8 methoxy group (moxifloxacin, gatifloxacin) substantially enhances anaerobic and gram-positive activity; unsubstituted C8 limits anaerobic spectrum.
- Naphthyridines (nalidixic acid, trovafloxacin) replace one benzene ring carbon with N for different spectrum profiles.